



Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023

November 8, 2023

SAN FRANCISCO--(BUSINESS WIRE)--Nov. 8, 2023-- [Better Therapeutics, Inc.](#) (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023.

To access the conference call, please register at: <https://register.vevent.com/register/BI7ccccb1e37c44102b4f5ce26d785604d>. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. The live webcast may be accessed by visiting the event link at: <https://edge.media-server.com/mmc/p/dk6kxzaw>. A replay of the webcast may be accessed from the Presentations & Events page in the Investors section of the Better Therapeutics corporate website at: <https://investors.bettertx.com>.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address underlying factors that sustain or worsen cardiometabolic diseases. The Company has developed a proprietary platform for the development of FDA-regulated, software-based solutions and in July 2023 received FDA authorization for [AspyreRx](#)TM to treat adults with type 2 diabetes. The CBT delivered by Better Therapeutics' PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics' clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com and aspyrtrx.com.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20231108041737/en/>

Investor Relations:

Mark Heinen

IR@bettertx.com

Media Enquiries:

Emma Williams

emma.williams@bettertx.com

Source: Better Therapeutics